Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Hodgkin Disease × Radiotherapy × Clear all

Phase

Phase 2 42 Phase 3 14 Phase 1 6 Phase NA 5 Phase 1/2 3 Phase 4 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Esophageal Squamous Cell Carcinoma 6 Leukemia 5 Esophageal Neoplasms 5 Rectal Neoplasms 3 Lymphoma 3 Head and Neck Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma 2 Prostatic Neoplasms 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Oropharyngeal Neoplasms 2 Oligodendroglioma 2 Nasopharyngeal Carcinoma 2 Myelodysplastic Syndromes 2 Lung Neoplasms 2 Leukemia, T-Cell 2 Leukemia, Myeloid, Chronic-Phase 2 Leukemia, Myeloid, Acute 2 Leukemia, Myeloid, Accelerated Phase 2 Carcinoma 2 Astrocytoma 2 Anemia, Refractory, with Excess of Blasts 2 Adenocarcinoma Of Esophagus 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Sezary Syndrome 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1

Interventions

pembrolizumab 1 interferon gamma-1b 1 interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1 etoposide phosphate 1 camrelizumab 1 aldesleukin 1 Radiotherapy 1 Peripheral Blood Stem Cell Transplantation 1 Nivolumab 1 Melphalan 1 Lenograstim 1 Interleukin-2 1 Interferon-gamma 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Etoposide 1 Decitabine 1 Cytarabine 1 Cyclosporins 1 Cyclosporine 1 Carmustine 1 Brentuximab Vedotin 1 ABVD protocol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00784537 2018-02-08

HD0801

Fondazione Italiana Linfomi - ETS

Phase 2/3 Completed

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡